News

ビット カジノ 口コミeives

November 27, 2020
Kyorin Pharmaceutical Receives Marketing Approval for injectable New Quinolone Antibacterial Agent "Lasvic® Intravenous Drip Infusion Kit 150mg"
November 5, 2020
Summary of ビットカジノ 入金方法l Results (For the Second Quarter Ended September 30, 2020) [Japanese Standard]
November 5, 2020
Second Quarter ビットカジノ 入金方法l Results for the Fiscal Year Ending March 31, 2021 - Supplementary Information
November 5, 2020
The Revision of ビットカジノ 入金方法l Forecasts for Fiscal Year Ending March 31, 2021
November 2, 2020
Revision of ビットカジノ 入金方法l Forecasts
October 12, 2020
KYORIN assigns Intellectual Properties regarding KRP-203 to Priothera
September 30, 2020
Notice regarding the joint development and commercialization agreement for [AKP-009], a treatment agent for Benign Prostatic Hyperplasia
August 3, 2020
First Quarter ビットカジノ 入金方法l Results for the Fiscal Year Ending March 31, 2021 - Supplementary Information
August 3, 2020
Summary of ビットカジノ 入金方法l Results (For the First Quarter Ending Dec 31, 2021) [Japanese Standard]
August 3, 2020
KYORIN and Otonomy Signed License Agreement for Novel Candidate Compound for Sensorineural Hearing Loss
June 29, 2020
Kyorin Pharmaceutical obtains approval for additional indication for pediatric use of Flutiform® 50 Aerosol, a combination drug for asthma treatment
May 12, 2020
Summary of ビットカジノ 入金方法l Results (For the fiscal year ended March 31, 2020) [Japanese Standard]
May 12, 2020
ビットカジノ 入金方法l Results for the Fiscal Year Ending March 31, 2020- Supplementary Information
March 31, 2020
Release of Novel Coronavirus Detection Reagent "SARS-CoV-2 GeneSoC ER Kyorin"
February 5, 2020
Summary of ビットカジノ 入金方法l Results (For the Third Quarter Ended Dec 31, 2019) [Japanese Standard]
February 5, 2020
Third Quarter ビットカジノ 入金方法l Results for the Fiscal Year Ending March 31, 2020 - Supplementary Information
January 6, 2020
KYORIN and aTyr to Collaborate on Novel Immunomodulator
  • 1